南方财经11月21日电，天眼查工商信息显示，近日，哈尔滨裕诚生物技术有限公司成立，法定代表人为黄柏林，注册资本2000万人民币，经营范围含生物化 工产品技术研发、化妆品批发、化妆品零售、发酵过程优化技术研发、化工产品生产、化工产品销售、货物进出口、互联网销售等。股东信息显示，该公司 由哈三联（002900）全资持股。 | | 意公司 音老板 童关系 查风险 《在用的商业查询工具 | | | | --- | --- | --- | --- | | | 哈尔滨裕诚生物技术有限公司 × 天眼一下 家中小企业发展子基金旗下机构 | 給 应用 ▼ | | | 基本信息 5 | 法律诉讼 经营风险 经营信息 | 公司发展 | | | 工商信息 ● | | | | | 工商信息 历史工商信息0 | | | | | 企业名称 | 哈尔滨裕诚生物技术有限公司 | | | | 法定代表人 | 登记状态 ② 存续 黄 黄柏林 | | 케 | | | 成立日期 2025-11-21 | | | | 统一社会信用代码 2 | 91230109MAK1C8PD7C 注册资本 ② 2000万人民币 | | নি | | 工商注册号 | 2 ...

Market Overview - The chemical pharmaceutical sector experienced a decline of 0.23% on November 20, with Minsheng Health leading the drop [1] - The Shanghai Composite Index closed at 3931.05, down 0.4%, while the Shenzhen Component Index closed at 12980.82, down 0.76% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Hainan Haiyao (000566) with a closing price of 7.92, up 10.00% and a trading volume of 2.1875 million shares, totaling 1.634 billion yuan [1] - Kangyi Pharmaceutical (300086) closed at 12.15, up 8.97% with a trading volume of 1.4039 million shares, totaling 1.656 billion yuan [1] - Other significant gainers included Bibete (688759), Yuekang Pharmaceutical (688658), and Qianyan Bio (688221) with increases ranging from 5.43% to 7.73% [1] - Conversely, the following stocks faced declines: - Minsheng Health (301507) closed at 16.69, down 6.18% with a trading volume of 273,400 shares, totaling 463 million yuan [2] - Shanhua Pharmaceutical (300452) and Hasa Lian (002900) also saw declines of 4.45% and 4.12% respectively [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 1.233 billion yuan from institutional investors, while retail investors contributed a net inflow of 964 million yuan [2] - Notable capital flows included: - Hainan Haiyao (000566) had a net inflow of 25.3 million yuan from institutional investors, but a net outflow of 101 million yuan from retail investors [3] - Kangyi Pharmaceutical (300086) experienced a net inflow of 56.4 million yuan from institutional investors, while retail investors saw a net outflow of 67.9 million yuan [3]

Core Points - The Shanghai Composite Index closed at 3939.81 points, above the six-month moving average, with a decline of 0.81% [1] - The total trading volume of A-shares reached 1,945.96 billion yuan [1] - A total of 51 A-shares have surpassed the six-month moving average, with notable stocks showing significant deviation rates [1] Summary by Category Market Performance - The Shanghai Composite Index is currently at 3939.81 points, indicating a slight decline of 0.81% [1] - The total trading volume for A-shares today was 1,945.96 billion yuan [1] Stocks Surpassing Six-Month Moving Average - 51 A-shares have broken through the six-month moving average, with the highest deviation rates observed in: - Longxun Co., Ltd. with a deviation rate of 18.63% and a price increase of 20.00% [1] - Meideng Technology with a deviation rate of 14.56% and a price increase of 22.82% [1] - Jingchen Co., Ltd. with a deviation rate of 9.04% and a price increase of 11.90% [1] Additional Notable Stocks - Other stocks with significant performance include: - Guangyun Technology with a deviation rate of 8.67% and a price increase of 19.99% [1] - Qixin Group with a deviation rate of 8.30% and a price increase of 10.07% [1] - Haohan Deep Technology with a deviation rate of 6.70% and a price increase of 9.03% [1]

Company Overview - Harbin Sanlian Pharmaceutical Co., Ltd. is located in Harbin, Heilongjiang Province, established on June 21, 1996, and listed on September 22, 2017. The company specializes in the research, production, and sales of chemical drug formulations [1][2]. Financial Performance - As of November 10, 2023, Harbin Sanlian reported a revenue of 581 million yuan for the period from January to September 2025, a year-on-year decrease of 30.75%. The net profit attributable to the parent company was -209 million yuan, a significant decline of 614.61% [2]. - The company has cumulatively distributed 677 million yuan in dividends since its A-share listing, with 158 million yuan distributed over the past three years [3]. Stock Performance - On November 18, 2023, Harbin Sanlian's stock price increased by 2.34%, reaching 14.89 yuan per share, with a trading volume of 52.42 million yuan and a turnover rate of 2.05%. The total market capitalization stood at 4.711 billion yuan [1]. - Year-to-date, the stock price has risen by 54.30%, with a 2.69% increase over the last five trading days and a 12.12% increase over the last 20 days. However, it has seen a decline of 1.72% over the past 60 days [1]. Shareholder Information - As of November 10, 2023, the number of shareholders for Harbin Sanlian was 39,600, a decrease of 2.98% from the previous period. The average number of circulating shares per person increased by 3.07% to 4,419 shares [2]. Business Segmentation - The main revenue sources for Harbin Sanlian include: large-volume injections (32.00%), lyophilized powder injections (18.39%), solid preparations (17.39%), small-volume injections (14.34%), and other segments such as veterinary drugs (2.55%) and import/export trade (1.82%) [1].

资料显示，哈尔滨三联药业股份有限公司位于黑龙江省哈尔滨市利民开发区北京路，成立日期1996年6 月21日，上市日期2017年9月22日，公司主营业务涉及化学药品制剂的研发、生产和销售。主营业务收 入构成为：大输液32.00%，冻干粉针剂18.39%，固体制剂17.39%，小容量注射剂14.34%，其他(补 充)10.26%，兽药2.55%，进出口贸易1.82%，原料药1.73%，化妆品0.94%，医疗器械0.43%，功能食品 0.16%。 哈三联所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：黑龙江自贸区、小盘、 QFII持股、医疗美容、肝炎治疗等。 截至11月10日，哈三联股东户数3.96万，较上期减少2.98%；人均流通股4419股，较上期增加3.07%。 2025年1月-9月，哈三联实现营业收入5.81亿元，同比减少30.75%；归母净利润-2.09亿元，同比减少 614.61%。 分红方面，哈三联A股上市后累计派现6.77亿元。近三年，累计派现1.58亿元。 11月14日，哈三联盘中上涨2.00%，截至10:17，报15.29元/股，成交1.51亿元，换手率5.70%，总市值 48.3 ...

证券日报网讯哈三联11月12日在互动平台回答投资者提问时表示，截至2025年11月10日公司股东人数为 39589户。 （文章来源：证券日报） ...

Core Points - The Shanghai Composite Index closed at 3993.35 points, remaining above the six-month moving average, with a slight decline of 0.24% [1] - The total trading volume of A-shares reached 1,270.245 billion yuan [1] - A total of 49 A-shares have surpassed the six-month moving average today, with notable stocks showing significant deviation rates [1] Summary by Category Stock Performance - Notable stocks with high deviation rates include: - Qudongli (驱动力) with a deviation rate of 5.91% and a daily increase of 7.05% [1] - Lubridge Information (路桥信息) with a deviation rate of 5.60% and a daily increase of 13.08% [1] - Beiyikang (倍益康) with a deviation rate of 4.75% and a daily increase of 7.60% [1] - Other stocks that just crossed the six-month moving average include: - Qianyuan Pharmaceutical (仟源医药) and *ST Jinke (*ST金科) with smaller deviation rates [1] Trading Activity - The trading turnover rate for Qudongli was 3.59%, while Lubridge Information had a turnover rate of 6.91% [1] - The stock with the highest turnover rate was Aipeng Medical (爱朋医疗) at 19.33% with a daily increase of 10.57% [1] Market Trends - The overall market shows a mix of stocks performing well above the six-month moving average, indicating potential bullish sentiment in certain sectors [1]

Group 1 - The company is developing a new product, Palivizumab injection, aimed at treating influenza A or B, specifically targeting the H3N2 subtype, which is a prevalent seasonal flu strain in humans [2] - The company confirmed that the Palivizumab injection is being researched as a next-generation product to address resistance to Oseltamivir and severe cases of influenza [2] - The company will continue to advance the progress of its research and development products [2]

Group 1 - The flu concept is experiencing renewed activity, leading to significant stock movements in related companies [1] - Te Yi Pharmaceutical has achieved two consecutive trading limits, indicating strong market interest [1] - Bo Hui Innovation has reached a 20% daily limit increase, reflecting positive investor sentiment [1] Group 2 - Panlong Pharmaceutical has also hit the daily limit, showcasing its strong performance in the market [1] - Other companies such as Zhongsheng Pharmaceutical, Ha Sanlian, and Jinhua Co. have seen their stocks rise in response to the flu concept's resurgence [1]

Core Points - The company, Ha Sanlian (002900), announced that it and its subsidiaries have no overdue guarantees, no litigation related to guarantees, and no losses incurred from being ruled against in guarantee-related lawsuits [1] Summary by Category Company Announcement - Ha Sanlian has confirmed that there are no overdue guarantees [1] - The company stated that it is not involved in any litigation concerning guarantees [1] - There are no losses that the company is required to bear due to adverse rulings in guarantee-related cases [1]